Media stories about Hutchison China MediTech (NASDAQ:HCM) have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hutchison China MediTech earned a news impact score of 0.15 on Accern’s scale. Accern also assigned headlines about the company an impact score of 47.8831269714568 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Hutchison China MediTech (NASDAQ HCM) opened at $34.48 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.84 and a quick ratio of 1.73. Hutchison China MediTech has a 52 week low of $12.62 and a 52 week high of $42.25.
Separately, BidaskClub raised Hutchison China MediTech from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th.
Hutchison China MediTech Company Profile
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.
Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.